Nimotuzumab for advanced pancreatic neuroendocrine tumors with high EGFR
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a drug called nimotuzumab, which targets a protein (EGFR) found on some pancreatic neuroendocrine tumor cells. It may help slow or stop tumor growth in people whose tumors have high levels of EGFR and have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of pancreatic neuroendocrine tumor (pNET) that is well or moderately differentiated and cannot be removed by surgery or has spread to other parts of the body.
- Your tumor must have high levels of a protein called EGFR, as shown by a biopsy or prior surgery sample.
- Your disease must have grown or spread within the last 12 months.
- You must be 18 years or older and have a good performance status (able to care for yourself).
- Your liver, kidney, and blood counts must be within acceptable levels.
- You must not have had prior treatment with EGFR-targeted drugs, and you must not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Hear when a new Pancreatic Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.